AGO-OVAR 10/ABA-01 MIMOSA
Laufzeit: 01.01.2007 - 31.12.2009
Laufzeit: 01.01.2007 - 31.12.2009
A randomized, double blind, placebo controled, multicentre trial of Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response to first line chemotherapy